8-KLeadership Changes

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Sep 15, 2006)

Filed September 15, 2006For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) announced significant leadership changes through an 8-K filing on September 15, 2006, reporting events from September 10-12, 2006. The most impactful development for investors is the termination of Chief Executive Officer Peter R. Dolan, effective September 12, 2006. Mr. Dolan also resigned from the company's Board of Directors. In response to this departure, the Board appointed James M. Cornelius as Interim Chief Executive Officer, also effective September 12, 2006. Mr. Cornelius brings substantial experience, having previously served in interim CEO and Chairman roles at Guidant Corporation and as CFO at Eli Lilly and Company. Additionally, the Board elected Dr. Robert Sanders Williams to its Board of Directors, effective September 11, 2006, and appointed him to the new Science and Technology Committee.

Key Highlights

  • 1Peter R. Dolan has been terminated as Chief Executive Officer of Bristol-Myers Squibb, effective September 12, 2006.
  • 2Peter R. Dolan has resigned from the Bristol-Myers Squibb Board of Directors, effective September 12, 2006.
  • 3James M. Cornelius has been appointed as Interim Chief Executive Officer, effective September 12, 2006.
  • 4James M. Cornelius has a strong background, including interim CEO and Chairman roles at Guidant Corporation and CFO experience at Eli Lilly and Company.
  • 5Robert Sanders Williams, M.D. has been elected to the Bristol-Myers Squibb Board of Directors, effective September 11, 2006.
  • 6Dr. Williams has been appointed to the newly formed Science and Technology Committee of the Board.

Frequently Asked Questions

The 8-K filing does not provide specific reasons for Mr. Dolan's termination. It only states that he was terminated from his position as Chief Executive Officer and resigned from the Board of Directors.

James M. Cornelius has extensive experience in the pharmaceutical industry. He served as Chairman of the Board and interim Chief Executive Officer of Guidant Corporation, and previously held roles as Non-Executive Chairman and Senior Executive there. He also served as Chief Financial Officer of Eli Lilly and Company.

Dr. Williams' election to the Board and appointment to the Science and Technology Committee suggests a potential focus on innovation and scientific advancements for Bristol-Myers Squibb. The formation of this committee indicates a strategic emphasis on leveraging scientific and technological capabilities.

This filing announces an interim CEO. The timeframe for appointing a permanent CEO is not specified in this 8-K report. Investors will likely await further announcements from the company regarding this process.